Vanguard Group Inc Erasca, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Erasca, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 12,695,597 shares of ERAS stock, worth $32.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,695,597
Previous 12,727,425
0.25%
Holding current value
$32.1 Million
Previous $17.4 Million
7.53%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding ERAS
# of Institutions
149Shares Held
216MCall Options Held
258KPut Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA22.7MShares$57.5 Million1.52% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD20.3MShares$51.4 Million0.02% of portfolio
-
Vr Adviser, LLC New York, NY17.9MShares$45.2 Million4.49% of portfolio
-
Logos Global Management LP San Francisco, CA15MShares$38 Million2.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.5MShares$36.7 Million0.63% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $309M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...